Edgar Filing: NEKTAR THERAPEUTICS - Form 4

NEKTAR THERAPEUTICS	5			
Form 4 December 17, 2015				
,				OMB APPROVAL
FORM 4 UNITED		CURITIES AND EXCHAN Washington, D.C. 20549	GE COMMISSION	OMB 3235-0287 Number:
Section 16. Form 4 or Form 5 Filed pu	MENT OF CH ursuant to Section (a) of the Public	IANGES IN BENEFICIAL SECURITIES on 16(a) of the Securities Exo c Utility Holding Company A e Investment Company Act o	change Act of 1934, Act of 1935 or Sectior	Expires: January 31, 2005 Estimated average burden hours per response 0.5
(Print or Type Responses)				
1. Name and Address of Reporting ROBIN HOWARD W	Sym NEI	ssuer Name and Ticker or Trading bol KTAR THERAPEUTICS [TR]	Issuer	Reporting Person(s) to k all applicable)
(Last) (First) C/O NEKTAR THERAPEUTICS, 455 MIS BAY BOULEVARD SOUT	(Moi 12/1 SSION	ate of Earliest Transaction nth/Day/Year) 15/2015	below)	title 10% Owner below) sident & CEO
(Street)	Filed	Amendment, Date Original l(Month/Day/Year)	Applicable Line) _X_ Form filed by C	int/Group Filing(Check Dne Reporting Person Iore than One Reporting
SAN FRANCISCO, CA 94	158		Person	ore than one reporting
(City) (State)	(Zip)	Table I - Non-Derivative Securiti	es Acquired, Disposed of	, or Beneficially Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)		3. 4. Securities if TransactionAcquired (A) or Code Disposed of (D) ar) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Pr	Securities For Beneficially (I Owned (I Following (I Reported Transaction(s) (Instr. 3, and 4)	Ownership7. Nature of Indirectorm: DirectIndirectD) or IndirectBeneficial(I)OwnershipInstr. 4)(Instr. 4)
Reminder: Report on a separate lin	e for each class of			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	<u>(1)</u>	12/15/2015		А	56,250	(2)	12/14/2023	Common Stock	56,250
Stock Option	\$ 15.55	12/15/2015		А	67,500	(3)	12/14/2023	Common Stock	67,500

Edgar Filing: NEKTAR THERAPEUTICS - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships			
r g a constant a constant	Director	10% Owner	Officer	Other
ROBIN HOWARD W C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO, CA 94158	Х		President & CEO	
Signatures				

Date

Gil M. Labrucherie,	12/17/2015
Attorney-in-Fact	12/1//2013

**Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each restricted stock unit represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.

(2) This restricted stock unit vests over 3 years in equal quarterly installments.

(3) This stock option vests in equal monthly installments over the 4-year period following the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.